Drug Profile


Alternative Names: Aureobasidin A; LY 295337; NK 204; R 1061

Latest Information Update: 23 Aug 2000

Price : $50

At a glance

  • Originator Takara Shuzo
  • Developer Eli Lilly; Nippon Kayaku; Takara Shuzo
  • Class Antifungals; Cyclic peptides
  • Mechanism of Action Inositol phosphorylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 23 Aug 2000 Discontinued-I for Mycoses in USA (Unknown route)
  • 23 Aug 2000 Discontinued-I for Mycoses in Japan (Unknown route)
  • 15 Jul 1999 No-Development-Reported for Mycoses in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top